EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

Ratziu, 2010, A position statement on NAFLD/NASH based on the EASL 2009 special conference, J Hepatol, 53, 372, 10.1016/j.jhep.2010.04.008

Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD

Bellentani, 2000, Prevalence of and risk factors for hepatic steatosis in Northern Italy, Ann Intern Med, 132, 112, 10.7326/0003-4819-132-2-200001180-00004

Vernon, 2011, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults, Aliment Pharmacol Ther, 34, 274, 10.1111/j.1365-2036.2011.04724.x

Younossi, 2012, Nonalcoholic fatty liver disease in lean individuals in the United States, Medicine, 91, 319, 10.1097/MD.0b013e3182779d49

Fracanzani, 2008, Risk of severe liver disease in NAFLD with normal aminotransferase levels: a role for insulin resistance and diabetes, Hepatology, 48, 792, 10.1002/hep.22429

Marchesini, 2015, NAFLD incidence and remission: only a matter of weight gain and weight loss?, J Hepatol, 62, 15, 10.1016/j.jhep.2014.10.023

Chalasani, 2012, The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association, Hepatology, 55, 2005, 10.1002/hep.25762

Barrera, 2014, The role of diet and nutritional intervention for the management of patients with NAFLD, Clin Liver Dis, 18, 91, 10.1016/j.cld.2013.09.009

Chiu, 2014, Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials, Eur J Clin Nutr, 68, 416, 10.1038/ejcn.2014.8

Gerber, 2012, Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study, Aliment Pharmacol Ther, 36, 772, 10.1111/apt.12038

Anstee, 2013, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nat Rev Gastroenterol Hepatol, 10, 330, 10.1038/nrgastro.2013.41

Valenti, 2010, Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease, Hepatology, 51, 1209, 10.1002/hep.23622

Liu, 2014, Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma, J Hepatol, 61, 75, 10.1016/j.jhep.2014.02.030

Liu, 2014, TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease, Nat Commun, 5, 4309, 10.1038/ncomms5309

Dongiovanni, 2015, Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease, Hepatology, 61, 506, 10.1002/hep.27490

Valenti, 2010, I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease, Hepatology, 52, 1274, 10.1002/hep.23823

Nobili, 2014, A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease, J Pediatr Gastroenterol Nutr, 58, 632, 10.1097/MPG.0000000000000279

Ratziu, 2005, Sampling variability of liver biopsy in nonalcoholic fatty liver disease, Gastroenterology, 128, 1898, 10.1053/j.gastro.2005.03.084

Kleiner, 2012, Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research, Semin Liver Dis, 32, 3, 10.1055/s-0032-1306421

Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701

Bedossa, 2014, Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease, Hepatology, 60, 565, 10.1002/hep.27173

Brunt, 2011, Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings, Hepatology, 53, 810, 10.1002/hep.24127

Ekstedt, 2015, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up, Hepatology, 61, 1547, 10.1002/hep.27368

Brunt, 2009, Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network, Hepatology, 49, 809, 10.1002/hep.22724

Alkhouri, 2012, Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease, J Hepatol, 57, 1312, 10.1016/j.jhep.2012.07.027

Saadeh, 2002, The utility of radiological imaging in nonalcoholic fatty liver disease, Gastroenterology, 123, 745, 10.1053/gast.2002.35354

Fishbein, 2005, Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound, J Clin Gastroenterol, 39, 619, 10.1097/00004836-200508000-00012

Ryan, 2002, One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation, Liver Transpl, 8, 1114, 10.1053/jlts.2002.36740

Fedchuk, 2014, Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease, Aliment Pharmacol Ther, 40, 1209, 10.1111/apt.12963

Machado, 2013, Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal, J Hepatol, 58, 1007, 10.1016/j.jhep.2012.11.021

2015, EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis, J Hepatol, 63, 237, 10.1016/j.jhep.2015.04.006

Cusi, 2014, Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease, J Hepatol, 60, 167, 10.1016/j.jhep.2013.07.042

Kwok, 2014, Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease–the role of transient elastography and plasma cytokeratin-18 fragments, Aliment Pharmacol Ther, 39, 254, 10.1111/apt.12569

Vuppalanchi, 2014, Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 12, e2121, 10.1016/j.cgh.2014.05.010

Guha, 2008, Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers, Hepatology, 47, 455, 10.1002/hep.21984

McPherson, 2013, Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?, Eur J Gastroenterol Hepatol, 25, 652, 10.1097/MEG.0b013e32835d72cf

Wong, 2010, Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease, Hepatology, 51, 454, 10.1002/hep.23312

Castera, 2010, Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations, Hepatology, 51, 828

Wong, 2012, Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease, Am J Gastroenterol, 107, 1862, 10.1038/ajg.2012.331

Petta, 2015, The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease, Liver Int, 35, 1566, 10.1111/liv.12584

Vajro, 2012, Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee, J Pediatr Gastroenterol Nutr, 54, 700, 10.1097/MPG.0b013e318252a13f

Nobili, 2013, A 360-degree overview of paediatric NAFLD: recent insights, J Hepatol, 58, 1218, 10.1016/j.jhep.2012.12.003

Gaggini, 2013, Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease, Nutrients, 5, 1544, 10.3390/nu5051544

Alberti, 2005, Review article: chronic hepatitis C–natural history and cofactors, Aliment Pharmacol Ther, 22, 74, 10.1111/j.1365-2036.2005.02602.x

Koliaki, 2015, Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis, Cell Metab, 21, 739, 10.1016/j.cmet.2015.04.004

Yki-Jarvinen, 2014, Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome, Lancet Diabetes Endocrinol, 2, 901, 10.1016/S2213-8587(14)70032-4

Matthews, 1985, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, 28, 412, 10.1007/BF00280883

McPherson, 2015, Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management, J Hepatol, 62, 1148, 10.1016/j.jhep.2014.11.034

Pais, 2013, A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver, J Hepatol, 59, 550, 10.1016/j.jhep.2013.04.027

Bedogni, 2005, Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study, Hepatology, 42, 44, 10.1002/hep.20734

Frith, 2010, Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease, J Hepatol, 52, 112, 10.1016/j.jhep.2009.10.010

Caldwell, 2004, The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease, J Hepatol, 40, 578, 10.1016/j.jhep.2004.02.013

Aron-Wisnewsky, 2012, Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese, J Hepatol, 56, 225, 10.1016/j.jhep.2011.04.022

Gomez-Ambrosi, 2012, Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity, Int J Obes (Lond), 36, 286, 10.1038/ijo.2011.100

Chang, 2012, Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men, Int J Obes (Lond), 36, 1187, 10.1038/ijo.2011.247

Gomez-Ambrosi, 2014, Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy, Diabetes Care, 37, 2813, 10.2337/dc14-0937

Ghouri, 2010, Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data, Hepatology, 52, 1156, 10.1002/hep.23789

Gastaldelli, 2007, Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects, Gastroenterology, 133, 496, 10.1053/j.gastro.2007.04.068

Kotronen, 2008, Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects, Diabetes Care, 31, 165, 10.2337/dc07-1463

Loomba, 2012, Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis, Hepatology, 56, 943, 10.1002/hep.25772

Armstrong, 2014, Extrahepatic complications of nonalcoholic fatty liver disease, Hepatology, 59, 1174, 10.1002/hep.26717

American Diabetes Association, 2014, Standards of medical care in diabetes–2014, Diabetes Care, 37, S14, 10.2337/dc14-S014

Ortiz-Lopez, 2012, Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD), Diabetes Care, 35, 873, 10.2337/dc11-1849

Juurinen, 2007, Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes, Am J Physiol Endocrinol Metab, 292, E829, 10.1152/ajpendo.00133.2006

Llaurado, 2015, Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes, J Clin Endocrinol Metab, 100, 607, 10.1210/jc.2014-3050

Anderwald, 2002, Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle, Diabetes, 51, 3025, 10.2337/diabetes.51.10.3025

Singh, 2015, Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies, Clin Gastroenterol Hepatol, 13, 643, 10.1016/j.cgh.2014.04.014

Haflidadottir, 2014, Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease, BMC Gastroenterol, 14, 166, 10.1186/1471-230X-14-166

Kim, 2013, Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States, Hepatology, 57, 1357, 10.1002/hep.26156

Schwimmer, 2005, Histopathology of pediatric nonalcoholic fatty liver disease, Hepatology, 42, 641, 10.1002/hep.20842

Oni, 2013, A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?, Atherosclerosis, 230, 258, 10.1016/j.atherosclerosis.2013.07.052

Targher, 2010, Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease, N Engl J Med, 363, 1341, 10.1056/NEJMra0912063

Bhatia, 2012, Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?, Eur Heart J, 33, 1190, 10.1093/eurheartj/ehr453

Calori, 2011, Fatty liver index and mortality: the Cremona study in the 15th year of follow-up, Hepatology, 54, 145, 10.1002/hep.24356

Pacifico, 2014, Nonalcoholic fatty liver disease and the heart in children and adolescents, World J Gastroenterol, 20, 9055

Dyson, 2014, Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team, J Hepatol, 60, 110, 10.1016/j.jhep.2013.08.011

Wong, 2014, Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S., Hepatology, 59, 2188, 10.1002/hep.26986

Musso, 2014, Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis, PLoS Med, 11, e1001680, 10.1371/journal.pmed.1001680

Targher, 2010, Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients, Diabetologia, 53, 1341, 10.1007/s00125-010-1720-1

Kim, 2014, Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population, Heart, 100, 938, 10.1136/heartjnl-2013-305099

Hazlehurst, 2013, Non-alcoholic fatty liver disease in common endocrine disorders, Eur J Endocrinol, 169, R27, 10.1530/EJE-13-0296

Lindor, 2004, Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial, Hepatology, 39, 770, 10.1002/hep.20092

Bugianesi, 2005, A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease, Am J Gastroenterol, 100, 1082, 10.1111/j.1572-0241.2005.41583.x

Belfort, 2006, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med, 355, 2297, 10.1056/NEJMoa060326

Zelber-Sagi, 2006, A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 4, 639, 10.1016/j.cgh.2006.02.004

Dufour, 2006, Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol, 4, 1537, 10.1016/j.cgh.2006.09.025

Ratziu, 2008, Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial, Gastroenterology, 135, 100, 10.1053/j.gastro.2008.03.078

Aithal, 2008, Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis, Gastroenterology, 135, 1176, 10.1053/j.gastro.2008.06.047

Haukeland, 2009, Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial, Scand J Gastroenterol, 44, 853, 10.1080/00365520902845268

Harrison, 2009, Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial, Hepatology, 49, 80, 10.1002/hep.22575

Shields, 2009, The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial, Therap Adv Gastroenterol, 2, 157, 10.1177/1756283X09105462

Promrat, 2010, Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis, Hepatology, 51, 121, 10.1002/hep.23276

Ratziu, 2010, Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial, Hepatology, 51, 445, 10.1002/hep.23270

Sanyal, 2010, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, N Engl J Med, 362, 1675, 10.1056/NEJMoa0907929

Leuschner, 2010, High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial, Hepatology, 52, 472, 10.1002/hep.23727

Zein, 2011, Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial, Hepatology, 54, 1610, 10.1002/hep.24544

Lavine, 2011, Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial, JAMA, 305, 1659, 10.1001/jama.2011.520

Neuschwander-Tetri, 2015, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial, Lancet, 385, 956, 10.1016/S0140-6736(14)61933-4

Valenti, 2014, A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia, World J Gastroenterol, 20, 3002, 10.3748/wjg.v20.i11.3002

Takeshita, 2014, The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial, Diabetologia, 57, 878, 10.1007/s00125-013-3149-9

Sanyal, 2014, No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial, Gastroenterology, 147, e371, 10.1053/j.gastro.2014.04.046

Loomba, 2015, Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial), Hepatology, 61, 1239, 10.1002/hep.27647

Argo, 2015, Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial, J Hepatol, 62, 190, 10.1016/j.jhep.2014.08.036

Armstrong, 2015, Liraglutide safety and effi cacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet

Zelber-Sagi, 2011, Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence, World J Gastroenterol, 17, 3377, 10.3748/wjg.v17.i29.3377

Boden, 2009, High- or low-carbohydrate diets: which is better for weight loss, insulin resistance, and fatty livers?, Gastroenterology, 136, 1490, 10.1053/j.gastro.2009.03.019

Lazo, 2010, Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes, Diabetes Care, 33, 2156, 10.2337/dc10-0856

Perreault, 2012, Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study, Lancet, 379, 2243, 10.1016/S0140-6736(12)60525-X

Thoma, 2012, Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review, J Hepatol, 56, 255, 10.1016/j.jhep.2011.06.010

Ryan, 2013, The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease, J Hepatol, 59, 138, 10.1016/j.jhep.2013.02.012

Liangpunsakul, 2012, What should we recommend to our patients with NAFLD regarding alcohol use?, Am J Gastroenterol, 107, 976, 10.1038/ajg.2012.20

Kwon, 2014, Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease, Liver Int, 34, 129, 10.1111/liv.12230

Dunn, 2012, Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD), J Hepatol, 57, 384, 10.1016/j.jhep.2012.03.024

Ascha, 2010, The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, Hepatology, 51, 1972, 10.1002/hep.23527

Saab, 2014, Impact of coffee on liver diseases: a systematic review, Liver Int, 34, 495, 10.1111/liv.12304

Keating, 2012, Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis, J Hepatol, 57, 157, 10.1016/j.jhep.2012.02.023

Bacchi, 2013, Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial), Hepatology, 58, 1287, 10.1002/hep.26393

Petersen, 2005, Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes, Diabetes, 54, 603, 10.2337/diabetes.54.3.603

Vilar-Gomez, 2015, Weight loss via lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367, 10.1053/j.gastro.2015.04.005

Rodriguez, 2012, Physical activity: an essential component of lifestyle modification in NAFLD, Nat Rev Gastroenterol Hepatol, 9, 726, 10.1038/nrgastro.2012.200

Adams, 2005, The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies, J Hepatol, 42, 132, 10.1016/j.jhep.2004.09.012

Sanyal, 2015, Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop, Hepatology, 61, 1392, 10.1002/hep.27678

Younossi, 2014, Systematic review with meta-analysis: non-alcoholic steatohepatitis – A case for personalised treatment based on pathogenic targets, Aliment Pharmacol Ther, 39, 3, 10.1111/apt.12543

Mazzella, 2014, The role of medications for the management of patients with NAFLD, Clin Liver Dis, 18, 73, 10.1016/j.cld.2013.09.005

Ratziu, 2015, Current efforts and trends in the treatment of NASH, J Hepatol, 62, S65, 10.1016/j.jhep.2015.02.041

Tiikkainen, 2004, Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes, Diabetes, 53, 2169, 10.2337/diabetes.53.8.2169

Bhalla, 2012, Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis, Cancer Prev Res (Phila), 5, 544, 10.1158/1940-6207.CAPR-11-0228

Zhang, 2012, Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis, J Clin Endocrinol Metab, 97, 2347, 10.1210/jc.2012-1267

Vilsboll, 2012, Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials, BMJ, 344, d7771, 10.1136/bmj.d7771

Hoofnagle, 2013, Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis, Aliment Pharmacol Ther, 38, 134, 10.1111/apt.12352

Bjelakovic, 2007, Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis, JAMA, 297, 842, 10.1001/jama.297.8.842

Schurks, 2010, Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials, BMJ, 341, c5702, 10.1136/bmj.c5702

Klein, 2011, Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT), JAMA, 306, 1549, 10.1001/jama.2011.1437

Mudaliar, 2013, Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease, Gastroenterology, 145, e571, 10.1053/j.gastro.2013.05.042

Parker, 2012, Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis, J Hepatol, 56, 944, 10.1016/j.jhep.2011.08.018

Dongiovanni, 2015, Statin use and nonalcoholic steatohepatitis in at risk individuals, J Hepatol, 63, 705, 10.1016/j.jhep.2015.05.006

Valenti, 2007, Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study, Am J Gastroenterol, 102, 1251, 10.1111/j.1572-0241.2007.01192.x

Nobili, 2009, Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention, World J Gastroenterol, 15, 6017, 10.3748/wjg.15.6017

Mitchel, 2014, Review article: the management of paediatric nonalcoholic fatty liver disease, Aliment Pharmacol Ther, 40, 1155, 10.1111/apt.12972

Feldstein, 2009, The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years, Gut, 58, 1538, 10.1136/gut.2008.171280

Schauer, 2014, Bariatric surgery versus intensive medical therapy for diabetes–3-year outcomes, N Engl J Med, 370, 2002, 10.1056/NEJMoa1401329

Caiazzo, 2014, Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study, Ann Surg, 260, 893, 10.1097/SLA.0000000000000945

Lassailly, 2015, Bariatric surgery reduces features of non-alcoholic steatohepatitis in morbidly obese patients, Gastroenterology, 149, 377, 10.1053/j.gastro.2015.04.014

Charlton, 2011, Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States, Gastroenterology, 141, 1249, 10.1053/j.gastro.2011.06.061

Wang, 2014, Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 12, e391, 10.1016/j.cgh.2013.09.023

Heuer, 2012, Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience, Digestion, 86, 107, 10.1159/000339344

Sebagh, 2012, Twenty-year protocol liver biopsies: invasive but useful for the management of liver recipients, J Hepatol, 56, 840, 10.1016/j.jhep.2011.11.016